ChronoScale plans Ekso exit as Ekso Bionics stock shifts

Ekso Bionics stock faces a structural reset as its former public parent, ChronoScale Holdings, moves toward a planned divestiture of the Legacy Ekso business during fiscal 2027. A September 25, 2026 proxy filing says the separation follows a July 1, 2026 holding-company transaction that placed ChronoScale Holdings above its cloud operation and Ekso Bionics, Inc., the legacy exoskeleton unit.

Legacy Ekso is held for sale

According to StockTitan, ChronoScale's board approved the divestiture plan on May 29, 2026, and publicly announced it on June 4, 2026. The filing classifies Legacy Ekso as held for sale and as discontinued operations, giving the exoskeleton business a separate strategic status from the cloud platform.

The transaction changes the meaning of historical EKSO figures for investors. ChronoScale Corporation became the successor operating company after the May 5, 2026 business combination, while ChronoScale Holdings became the public parent on July 1, 2026, according to the September 25 filing.

November vote sets the next date

A November 6, 2026 stockholder meeting is scheduled to address matters linked to the new corporate structure. The preliminary proxy says holders of record on September 10, 2026 will vote at the meeting, with a 66.67 percent quorum requirement.

The latest SEC filing also shows that ChronoScale Intermediate, formerly Ekso Bionics Holdings, and Ekso Bionics, Inc. remain connected through financing arrangements. In a September 12, 2026 Form 8-K, ChronoScale reported an amendment to a secured promissory note agreement involving its subsidiary and the legacy Ekso guarantor, while the registered public security was identified under the CHRN symbol on the Nasdaq Capital Market.

Ekso business enters a new phase

Ekso Bionics develops wearable robotic systems for rehabilitation and mobility, including powered lower-limb and upper-body products. The planned fiscal 2027 divestiture makes ownership structure and the eventual buyer central to the stock story, while the November 6 meeting supplies the next dated corporate milestone.